Efudix is suitable for actinic keratoses and very early pre-invasive squamous cell carcinomas that are thin. Efudix is the most commonly used topical therapy for actinic keratosis and superficial basal cell carcinomas. Efudix is a chemotherapy agent, but has virtually no internal effects when used topically. When used for actinic keratosis, it has the ability to treat not just the obvious lesions, but can get rid of the subclinical ones as well. Nightly application is suggested, usually for two weeks, during which time the skin may become red and inflamed. The healing time takes about two weeks, but the cosmetic result is often outstanding with a cure rate of about 93 percent.